Summary
- Main use
- Correction of nutritional deficiencies through intravenous nutrition (fluids, electrolytes, amino acids, etc.)
- Who receives it
- Adults
- Adult administration
- ○ Adults: Determine the dose and infusion rate according to the capacity to eliminate fat and metabolize glucose; determine the dose and bag size according to the patient's condition, body weight, and nutritional requirements. - Patients with normal nutritional status or mild metabolic stress: 0.7–1.0 g/kg/day of amino acids (0.10–0.15 g nitrogen/kg) - Patients under moderate to high metabolic stress: Infuse 1.0–2.0 g/kg/day of amino acids (0.15–0.30 g nitrogen/kg). Generally, infuse 0.7–1.0 g/kg/day of total amino acids (0.10–0.15 g nitrogen/kg) through a peripheral or central vein; this corresponds to 36.17–51.67 mL/kg/day of this medicine. ○ Infusion rate: Do not exceed 2.3 mL/kg per hour (equivalent to 0.25 g/kg glucose, 0.09 g/kg amino acids, and 0.13 g/kg fat). Administration over 12–24 hours is recommended.
Ingredients
- L-Isoleucine1.48g
- L-Leucine1.93g
- L-Lysine Acetate2.18g
- L-Methionine1.13g
- L-Phenylalanine1.2g
- L-Threonine0.85g
- L-Tryptophan0.33g
- L-Valine1.4g
- L-Alanine1.5g
- L-Arginine2.03g
- L-Histidine0.6g
- L-Proline2.38g
- L-Serine1.25g
- Glycine2.98g
- L-Cysteine Hydrochloride Hydrate0.05g
- Monobasic Potassium Phosphate0.68g
- Sodium Acetate Hydrate4.015g
- Glucose120g
- Sodium Chloride321mg
- Potassium Chloride1491mg
- Magnesium Chloride Hydrate508mg
- Calcium Chloride Hydrate331mg
- Manufacturer
- JW Pharmaceutical Co., Ltd.
Efficacy & effects
Correction of nutritional deficiencies through intravenous nutrition (fluids, electrolytes, amino acids, etc.)
View approved original textHide original text
This medication provides hydration, electrolytes, amino acids, and necessary calories for patients who are unable to consume food orally or via the gastrointestinal tract. It helps improve the nutritional status of patients who have insufficient or restricted nutritional intake. It is primarily used in cases where gastrointestinal function is impaired, making regular meals or nutritional intake difficult. This treatment plays a crucial role in the recovery of the patient's overall health and maintenance of physical strength, and it is designed to supplement nutrition safely and effectively. Therefore, it is used to improve the nutritional status of such patients.
How it is given
Adult administration
○ Adults: Determine the dose and infusion rate according to the capacity to eliminate fat and metabolize glucose; determine the dose and bag size according to the patient's condition, body weight, and nutritional requirements. - Patients with normal nutritional status or mild metabolic stress: 0.7–1.0 g/kg/day of amino acids (0.10–0.15 g nitrogen/kg) - Patients under moderate to high metabolic stress: Infuse 1.0–2.0 g/kg/day of amino acids (0.15–0.30 g nitrogen/kg). Generally, infuse 0.7–1.0 g/kg/day of total amino acids (0.10–0.15 g nitrogen/kg) through a peripheral or central vein; this corresponds to 36.17–51.67 mL/kg/day of this medicine. ○ Infusion rate: Do not exceed 2.3 mL/kg per hour (equivalent to 0.25 g/kg glucose, 0.09 g/kg amino acids, and 0.13 g/kg fat). Administration over 12–24 hours is recommended.
Precautions
This medication must be used strictly according to a medical doctor's instructions. When administering this medication via intravenous injection, do not use the same infusion equipment as ceftriaxone. If the same infusion line must be used, it should be thoroughly cleaned before and after administration. Patients with allergies to egg, soy protein, or any components of this medication should not use it. Additionally, patients with specific electrolyte abnormalities such as hypernatremia, hyperchloremia, hyperkalemia, hyperphosphatemia, hypermagnesemia should avoid administration. Patients with severe heart disease, liver disease, kidney disorders, and severe myasthenia gravis, severe coagulopathies, or those in acute shock should also avoid using this medication. In patients with bacteremia or liver/kidney disorders, hyperosmolar dehydration, edema, heart failure, diabetes, and pancreatic disorders, this medication should be administered cautiously and under strict medical supervision. This medication contains sodium bisulfite which may cause allergic reactions or asthma attacks in some patients and should be used with caution. During administration, symptoms such as acidosis, hyperglycemia, liver dysfunction, hyperkalemia, gastrointestinal symptoms (nausea, vomiting), cardiovascular symptoms (palpitations, elevated blood pressure) may occur, so symptoms should be monitored closely. Since this medication is a hyperosmolar solution, intravenous irritation may occur when injected into peripheral veins; thus, the infusion rate should be controlled and the patient's condition closely monitored. In patients with poor nutritional status, administration should be started slowly, and the concentration of glucose should be adjusted gradually to prevent hyperglycemia or hypoglycemia. During administration, blood glucose, electrolytes, and liver and kidney function tests should be conducted regularly to check for any abnormalities. For pregnant or nursing women, safety has not been established; therefore, it should be administered cautiously only when necessary. In children, particularly infants under 2 years old, safety has not been confirmed, so it is better not to use it. In the elderly, physiological functions decline, so the infusion rate should be slow, and the dosage should be adjusted. In cases of overdose, symptoms such as acidosis, fluid overload, hyperglycemia, vomiting, and chills may occur, requiring immediate cessation of administration and possibly treatment such as dialysis. This medication should be administered slowly via intravenous injection and should be mixed just before administration for rapid use. It should be stored at room temperature and not frozen. Before use, check for discoloration or leakage of the solution, and do not use it if any abnormalities are found; it should be used quickly after opening. If mixing with other drugs, be sure to confirm compatibility and use as soon as possible after mixing. During administration of this medication, continuously monitor fluid balance and electrolyte status to prevent overload in patients with heart or lung diseases.
Side effects
- Edema
- cerebral edema
- pulmonary edema
- peripheral edema
- water intoxication
- hyperglycemia
- hyperosmolar diuresis
- thirst
- liver function abnormalities
- serum amino acid imbalance
Show 38 moreCollapse
- metabolic alkalosis
- systemic nitrogenemia
- hyperammonemia
- sensory loss
- coma
- hyperkalemia
- elevated BUN
- hives
- rash
- nausea
- vomiting
- chest discomfort
- palpitations
- tachycardia
- hypertension
- hypophosphatemia
- alkalosis
- diabetes mellitus
- osmotic diuresis
- dehydration
- rebound hypoglycemia
- elevated liver enzymes
- vitamin deficiency
- vitamin excess
- electrolyte imbalance
- pediatric hyperammonemia
- thrombophlebitis
- chills
- fever
- headache
- dyspnea
- respiratory arrest
- shock
- bronchospasm
- urethral spasm
- peripheral vasodilation
- hypertension
- hypotension
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a sealed container to avoid exposure to air and does not require special refrigeration, so it can be stored at room temperature. In other words, to maintain the medication's efficacy, keep the lid tightly closed and store it out of very hot or humid places.
Appearance and packaging
Appearance
A pale yellow transparent liquid filled in a transparent plastic container with one or more partitions inside.
Package unit
1100mL (Solution A: 600mL, Solution B: 500mL) / Case
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.